Patent · US Active

MCL-1 inhibitors

US11643400B2 · kind B2 · utility

3Cited by

3References

20Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Hang Chu · San Mateo, US
Juan A. Guerrero · Concord, US
Anna E. Hurtley · San Mateo, US
Tae H. Hwang · Dallas, US
Lan Jiang · Foster City, US
Darryl Kato · Foster City, US
Tetsuya Kobayashi · Pleasanton, US
John E. Knox · Redwood City, US
Scott E. Lazerwith · Foster City, US
Xiaofen Li · Thousand Oaks, US
David W. Lin · Berkeley, US
Jonathan William Medley · San Mateo, US
Michael L. Mitchell · Union City, US
Devan Naduthambi · San Bruno, US
Zachary Newby · San Francisco, US
Neil H. Squires · San Francisco, US
Vickie Hsiao-Wei Tsui · Burlingame, US
Chandrasekar Venkataramani · Redwood City, US
William J. Watkins · Saratoga, US
Hong Yang · Foster City, US

Key dates

Filing date	Feb 9, 2021
Grant date	May 9, 2023
Priority date	—
Expiry date	Jul 18, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.